CARICA PAPAYA MEDIATED GREEN SYNTHESIZED SILVER NANOPARTICLES

Objective: The present study was designed to biosynthesize NPs from leaves to study the reducing Ag+ions and stabilizing the particles and confirm AgNP synthesis by using various spectroscopy and microscopic methods.Methods: Bio-inspired AgNPs were rapidly synthesized at room temperature using fresh aqueous leaf extract of Carica papaya. A green and low-cost synthesis was effective in the formation of stable crystalline NPs in the solution. Amine, alkene and alkyl halides groups present in the Carica papaya leaf extract functioned as reducing as well as a stabilizing agent to produce shape controlled AgNPs.Results: SPR confirmed the formation of AgNPs in UV-Visible spectra at 445.7 nm. The XRD result also showed the presence of elemental Ag+as a crystalline nature. Study the functional groups responsible for the bio reduction of Ag+. HE-TEM and FE-SEM with EDX image showed spherical crystalline AgNPs.Conclusion: Hence, the plant-based bio AgNPs could be used in biomedical applications

GREEN BIOSYNTHESIS OF MAGNETIC IRON OXIDE NANOPARTICLES OF VITEX NEGUNDO AQUEOUS EXTRACT

Objective: The green synthesis of magnetic iron oxide nanoparticles is a convenient, economical, rapid and eco-friendly method compared to physical and chemical synthesis methods.Methods: In the present study iron oxide nanoparticles synthesized by Vitex negundo leaves extract.Results: The formation of iron oxide nanoparticles was confirmed by the colour change and further characterized by UV-Visible Spectroscopy and XRD. The morphology and the size of nanoparticles were analyzed by SEM and HR-TEM analysis.Conclusion: On the basis of this research work, green synthesized iron oxide nanoparticles can be a good source for alternative therapy for human diseases

A new analytical method for determination of dolutegravir and rilpivirine in pharmaceutical formulations by RP-HPLC method

A simple, rapid, precise, sensitive and reproducible reverse phase high performance liquid chromatography (RP-HPLC) method has been developed for the quantitative analysis of Dolutegravir and Rilpivirine in pharmaceutical dosage form. Chromatographic separation of Dolutegravir and Rilpivirine was achieved on Waters Alliance -2695, by using Luna C18 (250mm x 4.6mm, 5µm) column and the mobile phase containing 0.1% OPA & ACN in the ratio of 50:50 v/v. The flow rate was 1.0 ml/min, detection was carried out by absorption at 245 nm using a photodiode array detector at ambient temperature. The number of theoretical plates and tailing factor for Dolutegravir and Rilpivirine were NLT 2000 and should not more than 2 respectively. The linearity of the method was excellent over the concentration range 10-150 µg/ml and 5-75 µg/ml for Dolutegravir and Rilpivirine respectively. The correlation coefficient was 0.999. % Relative standard deviation of peak areas of all measurements always less than 2.0. The proposed method was validated according to ICH guidelines. The method was found to be simple, economical, suitable, precise, accurate & robust method for quantitative analysis of Dolutegravir and Rilpivirine study of its stability

Two case reports of accessory cavitated uterine mass-diagnostic challenges

Accessory and cavitated uterine mass (ACUM) is a rare Mullerian duct anomaly of unknown incidence, affects young women. ACUM symptoms such as dysmenorrhea and chronic pelvic pain (CPP) resistant to common analgesics and hormonal contraceptives. Here we report two ACUM cases in our hospital within one year of period with different clinical manifestations. The idea behind reporting this-cases is to increase awareness of the above entity and for concurrent surgical treatment.

Biomass energy technology transfer Strategies for large-scale diffusion in India

Bioenergy technologies (BETs) have potential to meet India's energy needs in a sustainable way, particularly for the vast rural areas. India is a pioneer in research and development of certain BETs such as biogas, improved cookstoves and small scale biomass gasifiers. However, developments on more advanced BETs have taken place outside India. Unless the process of technology transfer mechanisms at various levels is promoted and managed effectively, the potential benefits of these technologies to the society and environment at large may not be fully realized. This article attempts to understand the technology transfer and diffusion process for BETs, analyzes the barriers to their transfer and diffusion and finally suggests strategies for their large-scale diffusion in India

Mechanism of action of VP1-001 in cryAB(R120G)-associated and age-related cataracts

PurposeWe previously identified an oxysterol, VP1-001 (also known as compound 29), that partially restores the transparency of lenses with cataracts. To understand the mechanism of VP1-001, we tested the ability of its enantiomer, ent-VP1-001, to bind and stabilize αB-crystallin (cryAB) in vitro and to produce a similar therapeutic effect in cryAB(R120G) mutant and aged wild-type mice with cataracts. VP1-001 and ent-VP1-001 have identical physicochemical properties. These experiments are designed to critically evaluate whether stereoselective binding to cryAB is required for activity.MethodsWe compared the binding of VP1-001 and ent-VP1-001 to cryAB using in silico docking, differential scanning fluorimetry (DSF), and microscale thermophoresis (MST). Compounds were delivered by six topical administrations to mouse eyes over 2 weeks, and the effects on cataracts and lens refractive measures in vivo were examined. Additionally, lens epithelial and fiber cell morphologies were assessed via transmission electron microscopy.ResultsDocking studies suggested greater binding of VP1-001 into a deep groove in the cryAB dimer compared with ent-VP1-001. Consistent with this prediction, DSF and MST experiments showed that VP1-001 bound cryAB, whereas ent-VP1-001 did not. Accordingly, topical treatment of lenses with ent-VP1-001 had no effect, whereas VP1-001 produced a statistically significant improvement in lens clarity and favorable changes in lens morphology.ConclusionsThe ability of VP1-001 to bind native cryAB dimers is important for its ability to reverse lens opacity in mouse models of cataracts

A double-blind study to determine the maximum tolerated dose of ethionamide, when administered twice-weekly to patients with pulmonary tuberculosis

ATI earlier report from this Centre (Tuber-culosis Chemotherapy Centre, Madras, 1964) showed that a fully supervised twice-weekly regimen of streptomycin plus high-dosage isoniazid was highly effective in the treatment of patients with newly-diagnosed bacteriologi-cally confirmed pulmonary tuberculosis. How-ever, this regimen involves intramuscular injections of streptomycin and may not always be easy to organize, especially in rural areas and in developing countries with limited resources. For this reason, it was decided to investigate the possibility of replacing strepto-mycin in the twice-weekly regimen by two oral drugs, namely ethionamide and PAS. Ethiona-mide was chosen since, apart from isoniazid and streptomycin, it was the most potent drug available at the time, and PAS was included with a view to enhance the efficacy of the regimen. Finally, it was decided that the patients should be given an intensive phase of daily treatment with streptomycin, PAS and isoniazid for two weeks. Experiments in the guinea-pig had shown that the size of the individual dose of a drug needed to be increased as the interval between successive doses was increased (Dickinson & Mitchison, 1966). As PAS is bulky and the dosage of isoniazid in the twice-weekly regimen was already high, namely 15 mg./kg. body-weight, it was decided to explore the possibility of increasing the dosage of ethionamide to a level higher than that usually employed (0.5— 1.0 g.) in daily regimens. An investigation was therefore undertaken to determine the maximum tolerated dose of ethionamide. when administered twice-weekly together with isonia-zid plus PAS. Since the assessment of ethio-namide intolerance is largely subjective, the study was conducted ‘double-blind’ with respect to the dosage of ethionamide